{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:59:44Z","timestamp":1791050384012,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"AbbVie GK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10384-021-00897-7","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T12:03:11Z","timestamp":1642593791000},"page":"130-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis"],"prefix":"10.1007","volume":"66","clinical-trial-number":[{"clinical-trial-number":"umin000032390","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5016-851X","authenticated-orcid":false,"given":"Kenichi","family":"Namba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sentaro","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Azumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Tsuruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Kaburaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"897_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40123-014-0023-x","volume":"3","author":"C Castiblanco","year":"2014","unstructured":"Castiblanco C, Foster CS. Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther. 2014;3:17\u201336.","journal-title":"Ophthalmol Ther"},{"key":"897_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fphar.2020.00655","volume":"11","author":"RA Valenzuela","year":"2020","unstructured":"Valenzuela RA, Flores I, Urrutia B, Fuentes F, Sabat PE, Llanos C, et al. New pharmacological strategies for the treatment of non-infectious uveitis. A minireview. Front Pharmacol. 2020;11:655.","journal-title":"Front Pharmacol"},{"key":"897_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.24920\/J1001-9242.2007.007","volume":"32","author":"C Zhao","year":"2017","unstructured":"Zhao C, Zhang M. Immunosuppressive treatment of non-infectious uveitis: history and current choices. Chin Med Sci J. 2017;32:48\u201361.","journal-title":"Chin Med Sci J"},{"key":"897_CR4","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2147\/OPTH.S94866","volume":"10","author":"A Baltmr","year":"2016","unstructured":"Baltmr A, Lightman S, Tomkins-Netzer O. Vogt-Koyanagi-Harada syndrome - current perspectives. Clin Ophthalmol. 2016;10:2345\u201361.","journal-title":"Clin Ophthalmol"},{"key":"897_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/1759720X15591310","volume":"7","author":"S Kobak","year":"2015","unstructured":"Kobak S. Sarcoidosis: a rheumatologist\u2019s perspective. Ther Adv Musculoskelet Dis. 2015;7:196\u2013205.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"897_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/25785826.2019.1678961","volume":"42","author":"K Maruyama","year":"2019","unstructured":"Maruyama K. Current standardized therapeutic approach for uveitis in Japan. Immunol Med. 2019;42:124\u201334.","journal-title":"Immunol Med"},{"key":"897_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492\u2013513.","journal-title":"Am J Ophthalmol"},{"key":"897_CR8","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/bjophthalmol-2020-317354","volume":"105","author":"H Takase","year":"2021","unstructured":"Takase H, Acharya NR, Babu K, Bodaghi B, Khairallah M, McCluskey PJ, et al. Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis. Br J Ophthalmol. 2021;105:1515\u20139.","journal-title":"Br J Ophthalmol"},{"key":"897_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"897_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75:952\u20137.","journal-title":"Ann Rheum Dis"},{"key":"897_CR11","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru N, van der Goes MC, Jacobs JWG, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72:1905\u201313.","journal-title":"Ann Rheum Dis"},{"key":"897_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","volume":"103","author":"SC Manson","year":"2009","unstructured":"Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103:975\u201394.","journal-title":"Respir Med"},{"key":"897_CR13","unstructured":"Ministry of Health, Welfare and Labour. Ethical guidelines for medical and health research involving human subjects. 2008. https:\/\/www.mhlw.go.jp\/general\/seido\/kousei\/i-kenkyu\/rinsyo\/dl\/shishin.pdf. Accessed 22 Apr 2021."},{"key":"897_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","volume":"131","author":"RW Read","year":"2001","unstructured":"Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647\u201352.","journal-title":"Am J Ophthalmol"},{"key":"897_CR15","first-page":"768","volume":"46","author":"K Sugisaki","year":"2008","unstructured":"Sugisaki K. Diagnostic guidelines and criteria for sarcoidosis\u20142006. Nihon Kokyuki Gakkai Zasshi. 2008;46:768\u201380 (in Japanese).","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"897_CR16","unstructured":"Japan Society of Sarcoidosis and Other Granulomatous Disorders. Diagnosis criteria and classification of disease severity. 2015. https:\/\/www.jssog.com\/wp\/wp-content\/themes\/jssog\/images\/system\/guidance\/1-2.pdf. Accessed 22 Apr 2021."},{"key":"897_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509\u201316.","journal-title":"Am J Ophthalmol"},{"key":"897_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","volume":"92","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467\u201371.","journal-title":"Ophthalmology"},{"key":"897_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3414\/ME12-01-0063","volume":"52","author":"B Trusko","year":"2013","unstructured":"Trusko B, Thorne J, Jabs D, Belfort R, Dick A, Gangaputra S, et al. The Standardization of Uveitis Nomenclature (SUN) project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52:259\u201365 (S1-6).","journal-title":"Methods Inf Med"},{"key":"897_CR20","unstructured":"American Academy of Ophthalmology. Practicing ophthalmologists curriculum 2014\u20132016. https:\/\/www.aao.org\/assets\/3a0a9dfd-e769-4e96-b49d-36c504fb518a\/635222148920430000\/core-2014-pdf. Accessed 4 Jan 2022."},{"key":"897_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.autrev.2014.04.001","volume":"13","author":"Y Jamilloux","year":"2014","unstructured":"Jamilloux Y, Kodjikian L, Broussolle C, S\u00e8ve P. Sarcoidosis and uveitis. Autoimmun Rev. 2014;13:840\u20139.","journal-title":"Autoimmun Rev"},{"key":"897_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2016.05.002","volume":"62","author":"GA O'Keefe","year":"2017","unstructured":"O\u2019Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol. 2017;62:1\u201325.","journal-title":"Surv Ophthalmol"},{"key":"897_CR23","first-page":"150","volume":"41","author":"Japanese Society of Sarcoidosis and Other Granulomatous Disorders","year":"2003","unstructured":"Japanese Society of Sarcoidosis and Other Granulomatous Disorders, Japanese Respiratory Society, Japanese College of Cardiology, Japanese Ophthalmological Society, MHLW Study Group of Diffuse Lung Disease. Opinion \u2013 2003 about sarcoidosis treatment. Nihon Kokyuki Gakkai Zasshi. 2003;41:150\u20139 (in Japanese).","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"897_CR24","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1\u2013106.","journal-title":"Gut"},{"key":"897_CR25","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention, 2020. https:\/\/ginasthma.org\/wp-content\/uploads\/2020\/06\/GINA-2020-report_20_06_04-1-wms.pdf. Accessed 22 Apr 2021."},{"key":"897_CR26","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2020. https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/12\/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed 22 Apr 2021."},{"key":"897_CR27","doi-asserted-by":"publisher","first-page":"e000536","DOI":"10.1136\/rmdopen-2017-000536","volume":"6","author":"C Hua","year":"2020","unstructured":"Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020;6:e000536.","journal-title":"RMD Open"},{"key":"897_CR28","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1111\/j.1755-3768.2010.02055.x","volume":"89","author":"M-H Errera","year":"2011","unstructured":"Errera M-H, Fardeau C, Cohen D, Navarro A, Gaudric A, Bodaghi B, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt\u2013Koyanagi\u2013Harada disease. Acta Ophthalmol. 2011;89:e357\u201366.","journal-title":"Acta Ophthalmol"},{"key":"897_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/eye.2008.89","volume":"23","author":"TYY Lai","year":"2009","unstructured":"Lai TYY, Chan RPS, Chan CKM, Lam DSC. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond). 2009;23:543\u20138.","journal-title":"Eye (Lond)"},{"key":"897_CR30","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/acr.22365","volume":"66","author":"A Makol","year":"2014","unstructured":"Makol A, Davis JM 3rd, Crowson CS, Therneau TM, Gabriel SE, Matteson EL. Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort, 1980\u20131994 versus 1995\u20132007. Arthritis Care Res (Hoboken). 2014;66:1482\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"897_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5414\/CN109384","volume":"90","author":"B Su","year":"2018","unstructured":"Su B, Zhang Q, Lv J. Cryptococcal meningitis in adult patients with primary nephrotic syndrome. Clin Nephrol. 2018;90:390\u20135.","journal-title":"Clin Nephrol"},{"key":"897_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","volume":"5","author":"S Gale","year":"2018","unstructured":"Gale S, Wilson JC, Chia J, Trinh H, Tuckwell K, Collinson N, et al. Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK. Rheumatol Ther. 2018;5:327\u201340.","journal-title":"Rheumatol Ther"},{"key":"897_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.autrev.2013.10.013","volume":"13","author":"G Ruiz-Irastorza","year":"2014","unstructured":"Ruiz-Irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014;13:206\u201314.","journal-title":"Autoimmun Rev"},{"key":"897_CR34","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/rheumatology\/key009","volume":"57","author":"K Nawata","year":"2018","unstructured":"Nawata K, Nakamura J, Ikeda K, Furuta S, Nakajima H, Ohtori S, et al. Transitional changes in the incidence of osteonecrosis in systemic lupus erythematosus patients: focus on immunosuppressant agents and glucocorticoids. Rheumatology. 2018;57:844\u20139.","journal-title":"Rheumatology"},{"key":"897_CR35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","volume":"53","author":"I Ruiz-Arruza","year":"2014","unstructured":"Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina J-A, Moran M-A, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology. 2014;53:1470\u20136.","journal-title":"Rheumatology"},{"key":"897_CR36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","volume":"117","author":"RO Ka\u00e7maz","year":"2010","unstructured":"Ka\u00e7maz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576\u201384.","journal-title":"Ophthalmology"},{"key":"897_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1749-6632.1986.tb18533.x","volume":"465","author":"AG Palestine","year":"1986","unstructured":"Palestine AG, Nussenblatt RB, Chan CC. Treatment of intraocular complications of sarcoidosis. Ann N Y Acad Sci. 1986;465:564\u201374.","journal-title":"Ann N Y Acad Sci"},{"key":"897_CR38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932\u201343.","journal-title":"N Engl J Med"},{"key":"897_CR39","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183\u201392.","journal-title":"Lancet"},{"key":"897_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","volume":"125","author":"EB Suhler","year":"2018","unstructured":"Suhler EB, Ad\u00e1n A, Br\u00e9zin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125:1075\u201387.","journal-title":"Ophthalmology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-021-00897-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T13:03:09Z","timestamp":1645966989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-021-00897-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1007\/s10384-021-00897-7","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"30 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Namba, Grant (AbbVie, Mitsubishi Tanabe, Eisai, EP-CRSU), Speaker fee (Alcon, Pfizer, Novartis, Kowa, Senju, Mitsubishi Tanabe, Eisai, AbbVie, Santen, Celgene); H. Takase, Personal fee (Santen, Novartis, AbbVie, Senju, Eisai, Otsuka) and has a patent pending (Japanese Patent Application No. 2019\u2013107483); Y. Usui, Grant (ROHTO), Personal fee (Santen, Senju, Alcon, Kowa, AbbVie, Eisai, Mitsubishi Tanabe, Wakamoto, Novartis); F. Nitta, None; K. Maruyama, Grant (TOPCON); S. Kusuhara, Grant (Bayer, Alcon), Personal fee (Alcon, Bayer, Eisai, AbbVie, Kowa, Santen, Senju, Sanofi, Mitsubishi Tanabe, HOYA, Charmant); M. Takeuchi, None; A. Azumi, None; R. Yanai, None; Y. Kaneko, Grant (AbbVie); E. Hasegawa, Grant (AbbVie); K. Nakai, None; H. Tsuruga, Employee of AbbVie and owns AbbVie stocks; K. Morita, Employee of AbbVie; T. Kaburaki, Grant (Santen, Eisai, Novartis, AbbVie, Kowa, Senju, Wakamoto), Personal fee (AbbVie, Santen, Novartis, Eisai, Mitsubishi Tanabe, Kowa, Wakamoto, Senju, Ono).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}